1. Berges RR, Windeler J, Trampisch HJ, Senge T. 1995. Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group. Lancet 345:1529-32.
2. Martin DJ, Lluel P, Guillot E, Coste A, Jammes D, Angel I. 1997. Comparative alpha-1 adrenoceptor subtype selectivity and functional uroselectivity of alpha-1 adrenoceptor antagonists. J Pharmacol. Exp. Ther 282:228-35.
3. Chapple CR, Wyndaele JJ, Nordling J, Boeminghaus F, Ypma AF, Abrams P. 1996. Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol 29:155-67.
4. Biaggioni I. 2018. Orthostatic Hypotension in the Hypertensive Patient. Am J Hypertens 31:1255-9.
5. Welk B, McArthur E, Fraser LA, Hayward J, Dixon S, et al. 2015. The risk of fall and fracture with the initiation of a prostate-selective alpha antagonist: a population based cohort study. BMJ 351:h5398.